Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Leukemia

  Free Subscription


Articles published in Int J Hematol

Retrieve available abstracts of 102 articles:
HTML format



Single Articles


    November 2021
  1. KOBAYASHI S, Sano H, Mochizuki K, Ohara Y, et al
    Effects of second transplantation with T-cell-replete haploidentical graft using low-dose anti-thymocyte globulin on long-term overall survival in pediatric patients with relapse of leukemia after first allogeneic transplantation.
    Int J Hematol. 2021 Nov 25. pii: 10.1007/s12185-021-03266.
    PubMed     Abstract available


  2. NAKAMAE M, Nakamae H, Hashimoto M, Koh H, et al
    Predictive value of clinical examination parameters for cardiovascular adverse events during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors.
    Int J Hematol. 2021 Nov 17. pii: 10.1007/s12185-021-03259.
    PubMed     Abstract available


    October 2021
  3. HONDA Y, Muramatsu H, Nanjo Y, Hirabayashi S, et al
    A retrospective analysis of azacitidine treatment for juvenile myelomonocytic leukemia.
    Int J Hematol. 2021 Oct 29. pii: 10.1007/s12185-021-03248.
    PubMed     Abstract available


  4. INOUE Y, Nishimura N, Murai M, Matsumoto M, et al
    Prevention of acute graft-versus-host disease in adult T-cell leukemia-lymphoma patients who received mogamulizumab before allogeneic hematopoietic cell transplantation.
    Int J Hematol. 2021 Oct 27. pii: 10.1007/s12185-021-03250.
    PubMed     Abstract available


  5. SHIBATA S, Inano S, Watanabe M, Fujiwara K, et al
    Identification of an asymptomatic Shwachman-Bodian-Diamond syndrome mutation in a patient with acute myeloid leukemia.
    Int J Hematol. 2021 Oct 26. pii: 10.1007/s12185-021-03251.
    PubMed     Abstract available


  6. IKAWA Y, Takenaka M, Sakai Y, Noguchi K, et al
    Utility of 18F-FDG-PET for detecting acute lymphoblastic leukemia: a case series of pediatric acute lymphoblastic leukemia without hematological symptoms.
    Int J Hematol. 2021 Oct 13. pii: 10.1007/s12185-021-03232.
    PubMed     Abstract available


  7. NUKUI J, Tanaka M, Nakajima H
    A case of multiple brain abscesses due to Bacillus cereus during induction therapy for acute myeloid leukemia.
    Int J Hematol. 2021 Oct 7. pii: 10.1007/s12185-021-03226.
    PubMed    


  8. LEE SH, Yoon JH, Min GJ, Park SS, et al
    Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study.
    Int J Hematol. 2021 Oct 6. pii: 10.1007/s12185-021-03231.
    PubMed     Abstract available


  9. KAWANO N, Kimura S, Miura M, Tochigi T, et al
    Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL.
    Int J Hematol. 2021;114:509-516.
    PubMed     Abstract available


    September 2021
  10. DEMBITZ V, Lalic H, Tomic B, Smoljo T, et al
    All-trans retinoic acid induces differentiation in primary acute myeloid leukemia blasts carrying an inversion of chromosome 16.
    Int J Hematol. 2021 Sep 21. pii: 10.1007/s12185-021-03224.
    PubMed     Abstract available


  11. NAKAMAE H, Yamamoto M, Sakaida E, Kanda Y, et al
    Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year followup of the Japanese subgroup of the randomized ENESTnd trial.
    Int J Hematol. 2021 Sep 11. pii: 10.1007/s12185-021-03216.
    PubMed     Abstract available


  12. IZUMI A, Tachibana T, Ando T, Tanaka M, et al
    A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation.
    Int J Hematol. 2021 Sep 6. pii: 10.1007/s12185-021-03217.
    PubMed     Abstract available


    August 2021
  13. HAN W, Zhou F, Wang Z, Hua H, et al
    Mutational landscape of chronic myelomonocytic leukemia and its potential clinical significance.
    Int J Hematol. 2021 Aug 27. pii: 10.1007/s12185-021-03210.
    PubMed     Abstract available


    July 2021
  14. KAKO S, Hayakawa F, Imai K, Tanaka J, et al
    Optimal treatment for Philadelphia-negative acute lymphoblastic leukemia in first remission in the era of high-intensity chemotherapy.
    Int J Hematol. 2021 Jul 30. pii: 10.1007/s12185-021-03198.
    PubMed     Abstract available


  15. SATOH T, Kayano H, Watanabe A, Ohta A, et al
    Lethal macrophage-related complications of juvenile myelomonocytic leukemia with a blastic crisis: an autopsy case report.
    Int J Hematol. 2021 Jul 16. pii: 10.1007/s12185-021-03189.
    PubMed     Abstract available


    June 2021
  16. LV K, Cai C, Chen J, Xu M, et al
    Prognostic value of lymphoid marker CD7 expression in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in first morphological complete remission.
    Int J Hematol. 2021 Jun 26. pii: 10.1007/s12185-021-03182.
    PubMed     Abstract available


  17. MORI T, Kikuchi T, Yamazaki R, Koda Y, et al
    Phase 1 study of plerixafor in combination with total body irradiation-based myeloablative conditioning for allogeneic hematopoietic stem cell transplantation.
    Int J Hematol. 2021;113:877-883.
    PubMed     Abstract available


    May 2021
  18. ARAKAWA Y, Masutani S, Oshima K, Mitani Y, et al
    Asian population may have a lower incidence of hip osteonecrosis in childhood acute lymphoblastic leukemia.
    Int J Hematol. 2021 May 18. pii: 10.1007/s12185-021-03163.
    PubMed     Abstract available


  19. MORITA K, Sasaki K
    Current status and novel strategy of CML.
    Int J Hematol. 2021;113:624-631.
    PubMed     Abstract available


  20. KIMURA S
    Evolution of CML treatment.
    Int J Hematol. 2021;113:622-623.
    PubMed    


  21. SHAN M, Lu Y, Yang M, Wang P, et al
    Characteristics and transplant outcome of myeloid sarcoma: a single-institute study.
    Int J Hematol. 2021;113:682-692.
    PubMed     Abstract available


    April 2021
  22. KIDOGUCHI K, Ureshino H, Kizuka-Sano H, Yamaguchi K, et al
    Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute.
    Int J Hematol. 2021 Apr 27. pii: 10.1007/s12185-021-03156.
    PubMed     Abstract available


  23. CHUAH C, Koh LP, Numbenjapon T, Zang DY, et al
    Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial.
    Int J Hematol. 2021 Apr 13. pii: 10.1007/s12185-021-03144.
    PubMed     Abstract available


  24. KOBAYASHI T, Ubukawa K, Fujishima M, Takahashi N, et al
    Correlation between increased immune checkpoint molecule expression and refractoriness to blinatumomab evaluated by longitudinal T cell analysis.
    Int J Hematol. 2021;113:600-605.
    PubMed     Abstract available


    March 2021
  25. KONDO H, Kanayama T, Matsumura U, Urata T, et al
    Relapsed RUNX1-RUNX1T1-positive acute myeloid leukemia with pseudo-Chediak-Higashi granules.
    Int J Hematol. 2021 Mar 29. pii: 10.1007/s12185-021-03141.
    PubMed    


  26. BNAYA A, Ruchlemer R, Itzkowitz E, Gabbay E, et al
    Incidence, risk factors, and recognition of pseudohyperkalemia in patients with chronic lymphocytic leukemia.
    Int J Hematol. 2021 Mar 29. pii: 10.1007/s12185-021-03142.
    PubMed     Abstract available


  27. LEE H, Basso IN, Kim DDH
    Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia.
    Int J Hematol. 2021 Mar 27. pii: 10.1007/s12185-021-03126.
    PubMed     Abstract available


  28. NAKANO N, Takatsuka Y, Kubota A, Tokunaga M, et al
    Correction to: Cord blood transplantation with a reduced-intensity conditioning regimen using fludarabine and melphalan for adult T-cell leukemia/lymphoma.
    Int J Hematol. 2021 Mar 17. pii: 10.1007/s12185-021-03125.
    PubMed    


  29. MORISHIGE S, Miyamoto T, Eto T, Uchida N, et al
    Clinical features and chromosomal/genetic aberration in adult acute lymphoblastic leukemia in Japan: results of Fukuoka Blood & Marrow Transplant Group Studies ALL MRD 2002 and 2008.
    Int J Hematol. 2021 Mar 16. pii: 10.1007/s12185-021-03116.
    PubMed     Abstract available


  30. JUNG J, Lee E, Shim H, Park JH, et al
    Prediction of clinical outcomes through assessment of sarcopenia and adipopenia using computed tomography in adult patients with acute myeloid leukemia.
    Int J Hematol. 2021 Mar 10. pii: 10.1007/s12185-021-03122.
    PubMed     Abstract available


  31. NAKA K
    New routes to eradicating chronic myelogenous leukemia stem cells by targeting metabolism.
    Int J Hematol. 2021 Mar 5. pii: 10.1007/s12185-021-03112.
    PubMed     Abstract available


  32. CHOI EJ, Lee JH, Kim H, Choi Y, et al
    Autologous hematopoietic cell transplantation following high-dose cytarabine consolidation for core-binding factor-acute myeloid leukemia in first complete remission: a phase 2 prospective trial.
    Int J Hematol. 2021 Mar 2. pii: 10.1007/s12185-021-03099.
    PubMed     Abstract available


  33. URESHINO H
    Treatment-free remission and immunity in chronic myeloid leukemia.
    Int J Hematol. 2021 Mar 2. pii: 10.1007/s12185-021-03117.
    PubMed     Abstract available


    February 2021
  34. ISHIDA H, Yano M, Hasegawa D, Hori T, et al
    Prednisolone poor response is not an indication for HSCT in pediatric B-cell precursor acute lymphoblastic leukemia in first remission: results from JACLS ALL-02 study.
    Int J Hematol. 2021 Feb 28. pii: 10.1007/s12185-021-03110.
    PubMed     Abstract available


  35. TERAKURA S, Kuwatsuka Y, Sugita J, Takahashi S, et al
    Effect of methotrexate dose in graft-versus-host disease prophylaxis after single-unit cord blood transplantation in adult acute myeloid leukemia.
    Int J Hematol. 2021 Feb 21. pii: 10.1007/s12185-021-03097.
    PubMed     Abstract available


  36. NAKANO N, Takatsuka Y, Kubota A, Tokunaga M, et al
    Cord blood transplantation with a reduced-intensity conditioning regimen using fludarabine and melphalan for adult T-cell leukemia/lymphoma.
    Int J Hematol. 2021 Feb 16. pii: 10.1007/s12185-021-03102.
    PubMed     Abstract available


  37. AKAHOSHI Y, Arai Y, Nishiwaki S, Mizuta S, et al
    Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Int J Hematol. 2021 Feb 11. pii: 10.1007/s12185-021-03094.
    PubMed     Abstract available


  38. ONO R, Ashiarai M, Hirabayashi S, Mizuki K, et al
    Ruxolitinib for hematopoietic cell transplantation-associated hemophagocytic lymphohistiocytosis.
    Int J Hematol. 2021;113:297-301.
    PubMed     Abstract available


    January 2021
  39. LIU Z, Li Y, Shi C
    Monitoring minimal/measurable residual disease in B-cell acute lymphoblastic leukemia by flow cytometry during targeted therapy.
    Int J Hematol. 2021 Jan 27. pii: 10.1007/s12185-021-03085.
    PubMed     Abstract available


  40. KUMAMOTO T, Goto H, Ogawa C, Hori T, et al
    Correction to: FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group.
    Int J Hematol. 2021 Jan 23. pii: 10.1007/s12185-020-03077.
    PubMed    


  41. UENO T, Sugio Y, Ohta T, Uehara Y, et al
    Successful upfront cord blood transplantation for plasma cell leukemia in the first complete response after daratumumab therapy.
    Int J Hematol. 2021 Jan 22. pii: 10.1007/s12185-021-03082.
    PubMed     Abstract available


  42. SAKAMOTO H, Itonaga H, Sawayama Y, Kojima A, et al
    Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma with HTLV-1-associated myelopathy.
    Int J Hematol. 2021 Jan 10. pii: 10.1007/s12185-020-03075.
    PubMed     Abstract available


  43. NAKAMURA F, Arai H, Nannya Y, Ichikawa M, et al
    Development of Philadelphia chromosome-negative acute myeloid leukemia with IDH2 and NPM1 mutations in a patient with chronic myeloid leukemia who showed a major molecular response to tyrosine kinase inhibitor therapy.
    Int J Hematol. 2021 Jan 5. pii: 10.1007/s12185-020-03074.
    PubMed     Abstract available


  44. FENG Y, Fu J
    Auer rods aid in the diagnosis of mixed phenotype acute leukemia.
    Int J Hematol. 2021 Jan 4. pii: 10.1007/s12185-020-03069.
    PubMed    


  45. QUANN KA, Redner RL
    The eyes have it: CNS leukemia presenting as optic neuritis.
    Int J Hematol. 2021 Jan 4. pii: 10.1007/s12185-020-03065.
    PubMed    


  46. NAKANO T, Kobayashi R, Matsushima S, Hori D, et al
    Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma.
    Int J Hematol. 2021 Jan 3. pii: 10.1007/s12185-020-03071.
    PubMed     Abstract available


  47. LIU F, Xue S, Zhang Y, Yang J, et al
    Clostridium perfringens sepsis in three patients with acute leukemia and review of the literature.
    Int J Hematol. 2021 Jan 2. pii: 10.1007/s12185-020-03060.
    PubMed     Abstract available


  48. XUE YJ, Wang Y, Jia YP, Zuo YX, et al
    The role of minimal residual disease in specific subtypes of pediatric acute lymphoblastic leukemia.
    Int J Hematol. 2021 Jan 1. pii: 10.1007/s12185-020-03063.
    PubMed     Abstract available


  49. CAI Y, Liu C, Guo Y, Chen X, et al
    Long-term safety and efficacy of imatinib in pediatric patients with chronic myeloid leukemia: single-center experience from China.
    Int J Hematol. 2021 Jan 1. pii: 10.1007/s12185-020-03042.
    PubMed     Abstract available


  50. KINOSHITA H, Okamura D, Sato T, Taji Y, et al
    Cytokeratin expression in therapy-related leukemia.
    Int J Hematol. 2021 Jan 1. pii: 10.1007/s12185-020-03062.
    PubMed    


  51. ITO F, Miura M, Fujioka Y, Abumiya M, et al
    The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration.
    Int J Hematol. 2021;113:100-105.
    PubMed     Abstract available


    November 2020
  52. SAITO T, Hatta Y, Hayakawa F, Takahashi T, et al
    Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study Group.
    Int J Hematol. 2020 Nov 23. pii: 10.1007/s12185-020-03032.
    PubMed     Abstract available


  53. HOSONO N, Ookura M, Araie H, Morita M, et al
    Clinical outcomes of gemtuzumab ozogamicin for relapsed acute myeloid leukemia: single-institution experience.
    Int J Hematol. 2020 Nov 20. pii: 10.1007/s12185-020-03023.
    PubMed     Abstract available


  54. INABA T, Tsukamoto T, Fujita N, Kuroda J, et al
    Auer-bodies in cellular components other than typical myeloblasts.
    Int J Hematol. 2020;112:605-606.
    PubMed    


  55. KANAYAMA T, Imamura T, Mayumi A, Soma E, et al
    Functional analysis of a novel fusion protein PAX5-KIDINS220 identified in a pediatric Ph-like ALL patient.
    Int J Hematol. 2020;112:714-719.
    PubMed     Abstract available


    October 2020
  56. IZUTSU K, Yamamoto K, Kato K, Ishikawa T, et al
    Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Int J Hematol. 2020 Oct 23. pii: 10.1007/s12185-020-03024.
    PubMed     Abstract available


  57. ZHANG XW, Shen X, Long WY, Xiao H, et al
    Salt-inducible kinase inhibition sensitizes human acute myeloid leukemia cells to all-trans retinoic acid-induced differentiation.
    Int J Hematol. 2020 Oct 19. pii: 10.1007/s12185-020-03026.
    PubMed     Abstract available


  58. NAKATANI K, Matsuo H, Harata Y, Higashitani M, et al
    Inhibition of CDK4/6 and autophagy synergistically induces apoptosis in t(8;21) acute myeloid leukemia cells.
    Int J Hematol. 2020 Oct 17. pii: 10.1007/s12185-020-03015.
    PubMed     Abstract available


  59. AMITAI I, Abulafia AS, Raanani P, Lipton JH, et al
    Chronic myeloid leukemia in solid organ transplant patients: a case series.
    Int J Hematol. 2020 Oct 6. pii: 10.1007/s12185-020-03014.
    PubMed     Abstract available


  60. UCHIDA N, Matsumoto K, Sakura T, Hidaka M, et al
    Myeloablative intravenous busulfan-containing regimens for allo-HSCT in AML or MDS patients over 54 years old: combined results of three phase II studies.
    Int J Hematol. 2020;112:510-523.
    PubMed     Abstract available


    September 2020
  61. LIU B, Li T
    Relapsed acute monocytic leukemia presenting as histiocytic morphology.
    Int J Hematol. 2020 Sep 20. pii: 10.1007/s12185-020-02995.
    PubMed    


  62. CORTES J, Podoltsev N, Kantarjian H, Borthakur G, et al
    Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia.
    Int J Hematol. 2020 Sep 20. pii: 10.1007/s12185-020-02994.
    PubMed     Abstract available


  63. OYA S, Morishige S, Ozawa H, Sasaki K, et al
    Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.
    Int J Hematol. 2020 Sep 19. pii: 10.1007/s12185-020-03006.
    PubMed     Abstract available


  64. YABE M, Morio T, Tabuchi K, Tomizawa D, et al
    Long-term outcome in patients with Fanconi anemia who received hematopoietic stem cell transplantation: a retrospective nationwide analysis.
    Int J Hematol. 2020 Sep 19. pii: 10.1007/s12185-020-02991.
    PubMed     Abstract available


  65. MOROZOVA EA, Olisova OY, Nikitin EA
    Cutaneous manifestations of B-cell chronic lymphocytic leukemia.
    Int J Hematol. 2020 Sep 5. pii: 10.1007/s12185-020-02978.
    PubMed     Abstract available


  66. OKAMOTO S, Ureshino H, Kimura S
    J-SKI will be able to elucidate whether the renal function recover or not after discontinuation of tyrosine kinase inhibitors.
    Int J Hematol. 2020;112:429-430.
    PubMed    


    August 2020
  67. KIYOKI Y, Matsuoka R, Kaneta T, Nishikii H, et al
    (18)FDG-PET imaging and histopathology in neuroleukemiosis with acute myeloid leukemia.
    Int J Hematol. 2020 Aug 31. pii: 10.1007/s12185-020-02976.
    PubMed    


  68. KIHIRA K, Chelakkot VS, Kainuma H, Okumura Y, et al
    Close interaction with bone marrow mesenchymal stromal cells induces the development of cancer stem cell-like immunophenotype in B cell precursor acute lymphoblastic leukemia cells.
    Int J Hematol. 2020 Aug 30. pii: 10.1007/s12185-020-02981.
    PubMed     Abstract available


  69. HATTA Y, Hayakawa F, Yamazaki E
    JSH practical guidelines for hematological malignancies, 2018: I. leukemia-3. acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL).
    Int J Hematol. 2020 Aug 18. pii: 10.1007/s12185-020-02965.
    PubMed    


  70. SHIMODA K, Takahashi N, Kirito K, Iriyama N, et al
    JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN).
    Int J Hematol. 2020 Aug 11. pii: 10.1007/s12185-020-02964.
    PubMed    


  71. KUMAMOTO T, Goto H, Ogawa C, Hori T, et al
    FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group.
    Int J Hematol. 2020 Aug 6. pii: 10.1007/s12185-020-02962.
    PubMed     Abstract available


  72. KUROSAWA S, Yamaguchi H, Yamaguchi T, Fukunaga K, et al
    The prognostic impact of FLT3-ITD, NPM1 and CEBPa in cytogenetically intermediate-risk AML after first relapse.
    Int J Hematol. 2020;112:200-209.
    PubMed     Abstract available


  73. ANDO T, Sano H, Yokoo M, Kusaba K, et al
    Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donor.
    Int J Hematol. 2020;112:249-253.
    PubMed     Abstract available


    July 2020
  74. SAITO M, Hasegawa H, Yamauchi S, Nakagawa S, et al
    A high-throughput detection method for the clonality of Human T-cell leukemia virus type-1-infected cells in vivo.
    Int J Hematol. 2020 Jul 29. pii: 10.1007/s12185-020-02935.
    PubMed     Abstract available


  75. LI YW, Xu YF, Hu W, Qian SX, et al
    Acute myeloid leukemia during pregnancy: a single institutional experience with 17 patients and literature review.
    Int J Hematol. 2020 Jul 18. pii: 10.1007/s12185-020-02938.
    PubMed     Abstract available


  76. HUANG Y, Zhang L
    Intracellular rod-like crystals in chronic lymphocyte leukemia.
    Int J Hematol. 2020 Jul 14. pii: 10.1007/s12185-020-02933.
    PubMed    


  77. CHILMI S, Nakahata S, Fauzi YR, Ichikawa T, et al
    Development of anti-human CADM1 monoclonal antibodies as a potential therapy for adult T-cell leukemia/lymphoma.
    Int J Hematol. 2020 Jul 12. pii: 10.1007/s12185-020-02939.
    PubMed     Abstract available


  78. HENZAN H, Takase K, Kamimura T, Mori Y, et al
    Correction to: Measurable residual disease after the first consolidation predicts the outcomes of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
    Int J Hematol. 2020 Jul 8. pii: 10.1007/s12185-020-02932.
    PubMed     Abstract available


  79. ANDO T, Fujisawa S, Teshigawara H, Matsumura A, et al
    Computed tomography-defined sarcopenia: prognostic predictor of nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study.
    Int J Hematol. 2020;112:46-56.
    PubMed     Abstract available


  80. MARKLIN M, Hagelstein I, Hinterleitner C, Salih HR, et al
    CD105 (endoglin) as risk marker in AML patients undergoing stem cell transplantation.
    Int J Hematol. 2020;112:57-64.
    PubMed     Abstract available


    June 2020
  81. HORIBE K, Morris JD, Tuglus CA, Dos Santos C, et al
    A phase 1b study of blinatumomab in Japanese children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    Int J Hematol. 2020 Jun 20. pii: 10.1007/s12185-020-02907.
    PubMed     Abstract available


  82. SEKI Y, Nagano O, Koda R, Morita S, et al
    Pathological findings suggesting vascular endothelial damage in multiple organs in chronic myelogenous leukemia patients on long-term tyrosine kinase inhibitor therapy.
    Int J Hematol. 2020 Jun 18. pii: 10.1007/s12185-020-02913.
    PubMed     Abstract available


  83. KIMURA SI, Fujita H, Handa H, Hiramoto N, et al
    Real-world management of infection during chemotherapy for acute leukemia in Japan: from the results of a nationwide questionnaire-based survey by the Japan Adult Leukemia Study Group.
    Int J Hematol. 2020 Jun 18. pii: 10.1007/s12185-020-02921.
    PubMed     Abstract available


  84. URESHINO H, Kamachi K
    Vascular events may predict the prognosis of patients with chronic myeloid leukemia.
    Int J Hematol. 2020 Jun 12. pii: 10.1007/s12185-020-02889.
    PubMed    


  85. HENZAN H, Takase K, Kamimura T, Mori Y, et al
    Measurable residual disease after the first consolidation predicts the outcomes of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
    Int J Hematol. 2020 Jun 10. pii: 10.1007/s12185-020-02911.
    PubMed     Abstract available


  86. LUCIJANIC M, Krecak I
    Effect of age and comorbidities on the decline of glomerular filtration rate in chronic myeloid leukemia patients discontinuing tyrosine kinase inhibitors.
    Int J Hematol. 2020 Jun 9. pii: 10.1007/s12185-020-02915.
    PubMed    


  87. KANAYA M, Kondo T
    Diffuse alveolar hemorrhage during induction therapy for acute myeloid leukemia with inv(16)(p13.1q22).
    Int J Hematol. 2020 Jun 6. pii: 10.1007/s12185-020-02900.
    PubMed    


  88. ZHOU X, Zheng M, Wang Q, Aa J, et al
    Metabolomics analysis identifies lysine and taurine as candidate prognostic biomarkers for AML-M2 patients.
    Int J Hematol. 2020;111:761-770.
    PubMed     Abstract available


  89. TAKEDA R, Ishigaki T, Ohno N, Yokoyama K, et al
    Immunophenotypic analysis of cerebrospinal fluid reveals concurrent development of ATL in the CNS of a HAM/TSP patient.
    Int J Hematol. 2020;111:891-896.
    PubMed     Abstract available


    May 2020
  90. YOSHINO H, Nishiyama Y, Kamma H, Chiba T, et al
    Functional characterization of a germline ETV6 variant associated with inherited thrombocytopenia, acute lymphoblastic leukemia, and salivary gland carcinoma in childhood.
    Int J Hematol. 2020 May 4. pii: 10.1007/s12185-020-02885.
    PubMed     Abstract available


  91. SAWAKI A, Miyazaki K, Yamaguchi M, Takeuchi T, et al
    Genetic polymorphisms and vincristine-induced peripheral neuropathy in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone therapy.
    Int J Hematol. 2020;111:686-691.
    PubMed     Abstract available


  92. URESHINO H, Shindo T, Sano H, Kubota Y, et al
    Reconstitution of NK cells expressing KIR3DL1 is associated with reduced NK cell activity and relapse of CML after allogeneic hematopoietic stem cell transplantation.
    Int J Hematol. 2020;111:733-738.
    PubMed     Abstract available


  93. KAGEYAMA Y, Katayama N
    Ontogeny of human B1 cells.
    Int J Hematol. 2020;111:628-633.
    PubMed     Abstract available


    April 2020
  94. FUJITA H, Ishikawa Y, Yokoyama Y
    JSH practical guidelines for hematological malignancies, 2018: I. Leukemia-2. Acute promyelocytic leukemia (APL).
    Int J Hematol. 2020 Apr 28. pii: 10.1007/s12185-020-02884.
    PubMed    


  95. OKAMOTO S, Ureshino H, Kawaguchi A, Miyazono M, et al
    Assessment of estimated glomerular filtration rate in patients with chronic myeloid leukemia following discontinuation of tyrosine kinase inhibitors.
    Int J Hematol. 2020 Apr 18. pii: 10.1007/s12185-020-02880.
    PubMed     Abstract available


  96. HINO M, Matsumura I, Fujisawa S, Ishizawa K, et al
    Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia.
    Int J Hematol. 2020 Apr 11. pii: 10.1007/s12185-020-02878.
    PubMed     Abstract available


  97. SUZUMIYA J, Takizawa J
    Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?
    Int J Hematol. 2020 Apr 6. pii: 10.1007/s12185-020-02867.
    PubMed     Abstract available


  98. SABURI M, Ogata M, Satou T, Soga Y, et al
    Prognostic implications of TdT expression in acute myeloid leukemia with an intermediate-risk karyotype.
    Int J Hematol. 2020 Apr 6. pii: 10.1007/s12185-020-02871.
    PubMed     Abstract available


    March 2020
  99. YAMAGUCHI H, Inokuchi K
    No sex-related difference in achievement of treatment-free remission following treatment with tyrosine kinase inhibitors in chronic myeloid leukemia.
    Int J Hematol. 2020 Mar 31. pii: 10.1007/s12185-020-02865.
    PubMed    


    February 2020
  100. OKURA E, Saito S, Natsume T, Morita D, et al
    Multiple heterogeneous bone invasions of B lymphoblastic lymphoma with the TCF3/PBX1 fusion gene: a case report.
    Int J Hematol. 2020;111:163-165.
    PubMed    


  101. POLPRASERT C, Takeda J, Niparuck P, Rattanathammethee T, et al
    Novel DDX41 variants in Thai patients with myeloid neoplasms.
    Int J Hematol. 2020;111:241-246.
    PubMed     Abstract available


  102. UEDA T, Jo T, Okada K, Arai Y, et al
    Curative potential of fludarabine, melphalan, and non-myeloablative dosage of busulfan in elderly patients with myeloid malignancy.
    Int J Hematol. 2020;111:247-255.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: